PE20020871A1 - Moleculas de enlace terapeuticas - Google Patents

Moleculas de enlace terapeuticas

Info

Publication number
PE20020871A1
PE20020871A1 PE2002000106A PE2002000106A PE20020871A1 PE 20020871 A1 PE20020871 A1 PE 20020871A1 PE 2002000106 A PE2002000106 A PE 2002000106A PE 2002000106 A PE2002000106 A PE 2002000106A PE 20020871 A1 PE20020871 A1 PE 20020871A1
Authority
PE
Peru
Prior art keywords
ser
cdr2
cdr3
asn
thr
Prior art date
Application number
PE2002000106A
Other languages
English (en)
Inventor
Gregorio Aversa
Frank Kolbinger
Herrera Jose M Carballido
Jose W Saldanha
Andras Aszodi
Bruce M Hall
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20020871A1 publication Critical patent/PE20020871A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UNA MOLECULA DE ENLACE QUE COMPRENDE CUANDO MENOS UN SITIO DE ENLACE DE ANTIGENO, LA CUAL COMPRENDE EN LA SECUENCIA DE LAS REGIONES HIPERVARIABLES CDR1, CDR2, CDR3 TENIENDO LA CDR1 LA SECUENCIA DE AMINOACIDOS Asn-Tyr-Ile-Ile-His (NYIIH), TENIENDO LA CDR2 LA SECUENCIA DE AMINOACIDOS Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) Y TENIENDO LA CDR3 LA SECUENCIA DE AMINOACIDOS Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT). SE REFIERE TAMBIEN A UNA MOLECUAL DE ENLACE QUE COMPRENDE: a) UN PRIMER DOMINIO CON REGIONES HIPERVARIABLES CDR1, CDR2, CDR3 Y b) UN SEGUNDO DOMINIO QUE COMPRENDE LAS REGIONES HIPERVARIABLES CDR1', CDR2', CDR3' TENIENDO LA CDR1' LA SECUENCIA DE AMINOACIDOS Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ) TENIENDO LA CDR2' LA SECUENCIA DE AMINOACIDOS Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) Y TENIENDO LA CDR3' LA SECUENCIA DE AMINOACIDOS Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT). LA MOLECULA DE ENLACE SE SELECCIONA DE UN ANTICUERPO MONOCLONAL QUIMERICO O HUMANIZADO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA
PE2002000106A 2001-02-12 2002-02-11 Moleculas de enlace terapeuticas PE20020871A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0103389.3A GB0103389D0 (en) 2001-02-12 2001-02-12 Organic compounds

Publications (1)

Publication Number Publication Date
PE20020871A1 true PE20020871A1 (es) 2002-11-11

Family

ID=9908539

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000106A PE20020871A1 (es) 2001-02-12 2002-02-11 Moleculas de enlace terapeuticas

Country Status (26)

Country Link
US (1) US20040096901A1 (es)
EP (1) EP1421191B1 (es)
JP (2) JP2004533816A (es)
KR (1) KR100752029B1 (es)
CN (1) CN100529074C (es)
AR (1) AR035539A1 (es)
AT (1) ATE526409T1 (es)
BR (1) BR0207151A (es)
CA (1) CA2437963A1 (es)
CZ (1) CZ20032129A3 (es)
EC (1) ECSP034714A (es)
ES (1) ES2374554T3 (es)
GB (1) GB0103389D0 (es)
HK (1) HK1071769A1 (es)
HU (1) HUP0401560A3 (es)
IL (1) IL157136A0 (es)
MX (1) MXPA03007197A (es)
NO (1) NO20033549L (es)
NZ (1) NZ548865A (es)
PE (1) PE20020871A1 (es)
PL (1) PL369516A1 (es)
RU (2) RU2405790C2 (es)
SK (1) SK10082003A3 (es)
TW (1) TWI332524B (es)
WO (1) WO2002072832A2 (es)
ZA (1) ZA200305911B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
TW200521231A (en) * 2003-09-18 2005-07-01 Novartis Ag Therapeutic binding molecules
EP1851308B1 (en) 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US8569059B2 (en) 2006-08-02 2013-10-29 Newsouth Innovations Pty Limited Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8
AU2008258646A1 (en) * 2007-06-05 2008-12-11 Fondazione Centro San Raffaele Del Monte Tabor Induction of tolerogenic phenotype in mature dendritic cells
CN102686733A (zh) * 2009-10-16 2012-09-19 陶氏益农公司 树枝状聚合物纳米技术用于将生物分子投递入植物细胞中的用途
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2502631A1 (en) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3026060A1 (en) 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US20230374148A1 (en) 2020-10-15 2023-11-23 UCB Biopharma SRL Binding molecules that multimerise cd45

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
RU2170257C2 (ru) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
JPH09191886A (ja) * 1996-01-19 1997-07-29 Asahi Breweries Ltd ヒト高親和性ＩｇＥ受容体に対するヒト型化抗体、半キメラ抗体およびキメラ抗体

Also Published As

Publication number Publication date
CN1551919A (zh) 2004-12-01
PL369516A1 (en) 2005-04-18
TWI332524B (en) 2010-11-01
MXPA03007197A (es) 2003-12-04
NO20033549D0 (no) 2003-08-11
CN100529074C (zh) 2009-08-19
RU2003126168A (ru) 2005-03-10
BR0207151A (pt) 2004-10-05
AR035539A1 (es) 2004-06-02
HK1071769A1 (en) 2005-07-29
ATE526409T1 (de) 2011-10-15
HUP0401560A3 (en) 2012-09-28
NZ548865A (en) 2008-03-28
JP2004533816A (ja) 2004-11-11
RU2405790C2 (ru) 2010-12-10
US20040096901A1 (en) 2004-05-20
EP1421191A2 (en) 2004-05-26
CZ20032129A3 (cs) 2003-11-12
WO2002072832A2 (en) 2002-09-19
IL157136A0 (en) 2004-02-08
CA2437963A1 (en) 2002-09-19
EP1421191B1 (en) 2011-09-28
NO20033549L (no) 2003-10-10
WO2002072832A3 (en) 2004-03-25
KR20040036684A (ko) 2004-04-30
RU2328506C2 (ru) 2008-07-10
RU2008100239A (ru) 2009-07-20
ECSP034714A (es) 2003-09-24
GB0103389D0 (en) 2001-03-28
HUP0401560A2 (hu) 2004-11-29
ZA200305911B (en) 2004-06-28
ES2374554T3 (es) 2012-02-17
KR100752029B1 (ko) 2007-08-28
JP2009034108A (ja) 2009-02-19
SK10082003A3 (sk) 2004-03-02

Similar Documents

Publication Publication Date Title
PE20020871A1 (es) Moleculas de enlace terapeuticas
AR035581A1 (es) Anticuerpos para il-1beta humana
HRP20181069T1 (hr) Antagonistička protutijela na il-17
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
TNSN06087A1 (en) Therapeutic binding molecules
CY1124289T1 (el) Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
CO5280086A1 (es) Molecula de enlace de cd154, construccion de adn, vector de expresion, composcion y combinacion farmaceutica
PE20011219A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
HRP20020693B1 (en) HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID Abeta PEPTIDE
RS54271B1 (en) HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
AR046379A1 (es) Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento
RS52860B (en) ANTI-ILT7 ANTITELO
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
PL406852A1 (pl) Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α
ATE472556T1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
PE20050925A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
BRPI0513681A (pt) composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer
NO20061619L (no) Malsoking av tumorvaskulatur ved a benytte radiomerket antistoff L19 mot fibronectin ED-B
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
JPWO2020144178A5 (es)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed